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provided by nonprofessionals. The costs of indirect care were reported to be consider-
ably higher than the direct costs. Direct annual costs range from 1,869€ for Poland to 
22,230$ for the US. The costs for inpatient care generate the main part of the direct 
economic burden. In the majority of cases the economic impact is referred to the 
severity of the CHF expressed by the New York Heart Association functional clas-
sification (NYHA) stage. The more severe NYHA stages III and IV are associated with 
higher costs. ConClusions: Our review highlights the considerable and growing 
economic burden of CHF on the health care systems of developed countries. The 
COI studies included in this review show large variations in methodology used and 
the cost results vary as a consequence. Further research is needed to highlight the 
economic burden of indirect costs of CHF. High quality data from COI studies with a 
robust methodology applied can inform policy makers about the major cost drivers 
of CHF and can be used as the basis of further economic evaluations.
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objeCtives: Atrial Fibrillation (AF) is the most common sustained cardiac arrhyth-
mia. The increasing prevalence of AF and the advances in the management of the 
disease in recent years highlight the importance of updating cost of illness studies 
to understand both the financial burden and the related health care resource use. 
The main purpose of this study was to perform a cost analysis of AF hospitalized 
cases in a large general population of Italy from the perspective of the Health System 
(HS). Methods: This is an observational retrospective cohort study conducted 
using automatic health care administrative archives of the Italian publicly funded 
HS. The study cohort included all subjects living in Lombardy, a region of Northern 
Italy, with a hospital discharge for AF or flutter (index event) in the time period 1st 
January 2003 - 31st December 2009. A pre-index period of eligibility shorter than 3 
years was an exclusion criterion. Subjects were followed until 31stDecember 2010 or 
death or emigration, collecting data related to hospitalizations, drug prescriptions 
and outpatient visits and related direct costs. Results: The mean age of patients 
admitted to hospital with a diagnosis of AF was 72 years (± 14.1 standard deviation). 
Women were older than men and 50% of patients were male. Major comorbidities 
at index event were: congestive heart failure, cerebrovascular diseases, chronic 
pulmonary diseases and diabetes. The mean cost of index hospitalization was about 
3,600 € (± 3,900 € ). Survival at one year from index event was 83%, 66% at four years 
and 53% at seven years. The main driver of direct medical cost during follow-up 
was inpatient care, followed by drug therapies. ConClusions: AF resulted in a 
substantial medical cost, reflecting resource-intensive and long-term treatments. 
These costs accompanied with increasing prevalence of AF, justify increased atten-
tion to the management of patients with AF.
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objeCtives: Map and cost the patient pathway for acute and chronic heart fail-
ure patients in Ireland. Obtain the key cost parameters using a top down approach, 
whilst highlighting the economic and societal impact of this non communicable 
disease. Methods: A prevalence based top down approach was applied to estimate 
the cost of heart failure in Ireland for the year 2012, taking a societal perspective. 
Data on primary and all case diagnoses were obtained from the National Hospital 
In-Patient Enquiry Scheme (HIPE). Market research identified admissions in private 
hospital. Patients hospitalised with heart failure have been taken as representative 
of patients with Acute Decompensated Heart Failure (ADHF). All treatment pathways 
associated with the direct cost of both prevalent and incident cases of heart failure 
were confirmed and validated by health care professionals in primary and secondary 
care settings. Indirect and economic costs consisted of informal care and Life Years 
Lost (LYL), respectively. These were estimated using national surveys and registries, 
such as the Central Statistics Office (CSO). LYL were monetised using Irish specific 
life tables and the value of a statistical and/or the QALY threshold. Where data were 
lacking or uncertain, treatment algorithms were confirmed and validated through 
scientific engagement with key opinion leaders. Results:  The total cost of heart 
failure in Ireland for the year 2012 was estimated at € 662.3 million. Indirect and eco-
nomic costs were identified as the largest cost component at € 473.7m (76%), while the 
direct cost represented 24% of the cost burden. ConClusions: Once HF has devel-
oped, the pathophysiology of the condition is characterised by high morbidity and 
mortality, frequent hospitalisation, and a large reliance on informal care. This study 
identified large regional variation in available heart failure services, hence impacting 
the necessary follow up care. As a result, a substantial cost driver in the management 
and care of heart failure patients is informal care. This cost has not been considered 
in previous heart failure studies, making it an important area for future research.
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objeCtives: Trauma patients often experience significant hemorrhage and, there-
fore, may require more resources during hospitalization than patients who do not 
hemorrhage. The cost of blood/blood products is poorly understood in trauma patients 
and not well documented in the literature. Our objective was to evaluate the outcomes 
and cost of care for trauma patients based on bleeding status. Methods: Patients 
with costs and length of stay (LOS) greater than zero, discharged between January 1, 
2010 and December 31, 2012, were identified in the Premier Hospital Database based 
on select ICD9 codes. All costs were based on hospital reported costs. Patients who 
received blood products prior to the day of surgery were excluded. Multivariate regres-
had no recurrent CV events was estimated to be £10.4 billion versus £14.94 billion 
with recurring CV events under current SOC. This translated into a 43.8% higher 
economic burden on health care. ConClusions: The subsequent CV events in 
post-MI patients pose an additional economic burden of 44% on UK health care 
despite the current SoC. This indicates the need to design new interventions to 
reduce the risk of further CV events in post-MI patients.
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objeCtives: To estimate the costs of atherosclerotic and haemorrhagic events 
associated with Acute Coronary Syndrome (ACS) treated with ASA + Clopidogrel, 
in Turkish settings. Methods: An expert panel was organized to reflect the solid 
data regarding disease management patterns and options to Turkish payer for 
reimbursement process. Due to the multidisciplinary nature of the ACS, physi-
cians from the cardiology, neurology and cardiovascular surgery participated 
to panel. Cost components of bleeding events, haemorrhagic stroke, ischemic 
stroke, myocardial infarction and revascularization have been identified. Experts 
have reviewed their daily clinical practices and local & global literature for the 
related complications along with medical procedures. All cost components includ-
ing medications, hospitalization, surgical treatments follow up procedures and 
rehabilitation were considered. For the prices of medications, and diagnostic and 
therapeutic procedures, March 2014 local prices have been taken into account. 
For Turkish Lira: Euro conversion, Turkish Central Bank March 2013 currency rate 
(was used TL/Euro = 3.06). Results: The cost of MI in the first year is 2.004€ and 
376€ for the following years. (≈%70) of the cost comes from non-pharmacological 
treatment. Costs of ischemic and hemorrhagic stroke for the acute period and fol-
lowing three months are 2.266 € and 3.010€ , respectively. Annual cost of ischemic 
and haemorrhagic strokes are 2.951€ and 3.646€ for the first year. The main cost 
drivers for stroke are also non-pharmacological treatments, mainly physiotherapy 
for stroke. (≈%70-80 for the 1st year) Coronary revascularization costs 833€ for 
percutaneous interventionand 2.354€ for coronary by-pass. Bleeding costs are 
relatively low compared to other complications. Major and minor bleedings are 
189€ /event and 17€ /event. ConClusions: Costs of the ACS related complications 
are quite high. Especially acute phase of MI and stroke has significant burden of 
the budget. More effective secondary prevention of the ACS might reduce the 
burden of disease in the Turkish settings.
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objeCtives: The aim of this study has been determination of the burden of statins in 
the treatment of acute coronary syndrome (ACS) and angina pectoris (AP). There is a 
significant number of registered statins (brands and generics) in Belarus (lovastatin, 
atorvastatin simvastatin and rosuvastatin). Pharmacoeconomic studies of statins are 
topical because of the competition at the pharmaceutical market to ensure rational 
use of public and private funds. Methods: Overview of available statins has been 
conducted. Equivalent effective doses were established on the basis of the published 
data. “Cost of illness” has been calculated with the help of national clinical guidelines 
for treatment of ACS and AP. Comparison of the each statin burden by determining 
the proportion of funds falling at each one in the overall cost of the patient´s care has 
been made. Results: Cost of statins had no significant value in the overall “cost of 
illness” for acute coronary pathology (ranged from 0.3% to 1.88%). The cost of statins 
has a significant impact on the final “cost of illness” in the case of chronic cardiac 
pathology and ranges from 18.54% to 39.9%. Burden of rosuvastatin (Mertenil) in 
this analysis seems to be the most stable and predictable because of the changes 
in a narrow range (23.9% - 26.48% in the first year and 28.48% - 29.49% - the second 
and subsequent years) vs. atorvastatin (19.35% - 35.7% in the first year and 23.3% - 
39.9% in the second and subsequent years) and simvastatin (18.54% - 32.62% in the 
first year and 22.13% - 35.89% in the second and subsequent years). ConClusions: 
Pharmacoeconomic evaluation of statin choosing is important for prolonged use of 
medicines but not for short-term use in acute coronary syndrome.
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objeCtives: The aim of this study was to perform a systematic review of recently 
published Cost of Illness (COI) studies related to Chronic Heart Failure (CHF) to high-
light the increasing cost impact associated with the disease and identify the major 
cost drivers. Methods: A systematic review was conducted from 2004-2014 to 
identify COI studies related to CHF, searching the PubMed, Science Direct, Cochrane 
Library, Scopus and York CRD databases. The PRISMA guidelines were applied for the 
search. Results: 12 studies were included in this review and were grouped into a 
prevalence- and an incidence-based approach. Most articles were considering only 
the direct medical costs (hospitalization, medication, primary care) of CHF, while 
some of them also assessed the economic impact of indirect care, i.e. informal care 
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A485
Average costs of treating unstable angina were € 2,217 - 3,644 PA. Direct medical costs 
of chronic HF patients were between € 3,150 - 4,792 per patient per year. Average treat-
ment costs for hospitalized PAD in the acute phase were € 4,186 PA, € 2,138 during 
month 1-6 after initial hospitalization, € 1,350 in month 7-12, and € 1,172 in month 
13-18. For stroke, total direct medical costs in year one were € 11,408 per patient. Total 
direct medical costs during the 1st year after an ischemic stroke event were € 15,573 
- 18,517 per patient, € 5,280 in month 13-18, and € 5,479 per year in the subsequent 4 
years. ConClusions: MI, unstable angina, HF, stroke and PAD have a high financial 
impact on the German health care system. Treatment costs in the first year after event 
were highest for MI with € 11,672 – 12,713 per patient followed by stroke with € 11,408 
per patient demonstrating need for improvement in preventing CVE.
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objeCtives: Supraventricular tachycardias (SVT) are a group of arrhythmias which 
result in significant impairment of health-related quality of life (HRQoL). While not 
as common as atrial fibrillation, SVT are still a significant health care problem since 
an average time from the onset of symptoms to successful ablation exceeds 10 years 
both in highly and less developed countries. The aim of this study was to calculate 
an annual cost of conservative treatment of SVT in Poland. Methods: This was 
an economical part of The PPRA study (NCT01594814). PPRA was a single-center, 
prospective, cohort study conducted in tertiary care cardiology center in Poland. All 
data concerning health care resources utilization: outpatient and inpatient visits, 
emergency room (ER) consultations, drugs etc. were derived from the study. Costs of 
disease related groups (DRG), outpatient visits and reimbursed drugs were derived 
from official price lists of Polish National Health Fund (NHF). Costs of ER visits were 
calculated as a mean cost of visit derived from seven hospitals of different levels of 
care. Costs of medical transport were calculated as a mean cost derived from four 
different centers providing ambulance services. Cost of non-reimbursed drugs and 
of outpatient visits and diagnostic tests in private sector were calculated as a mean 
cost of those resources available on official websites of nation-wide providers. All 
costs are presented in Euro (EUR) as median [interquartile range]. Results: During 
1.5 years, 82 patients were enrolled and the data for this analysis was available for all 
patients. The yearly median cost of conservative treatment of SVT was EUR 415 [237-
727] from the NHS perspective and EUR 468 [280-793] from the societal perspective. 
Those costs were mainly driven by costs of hospitalizations and ER. ConClusions: 
Annual cost of conservative treatment of SVT is substantial and driven mainly by 
hospital services.
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objeCtives: The main purpose of study was to evaluate the utilization of implant-
able cardioverter defibrillator (ICD) with or without cardiac resynchronization pacing 
(CRT-D) in Lombardy, the most populated Italian region with universal health care 
coverage for about 10 million inhabitants, from 2000 to 2010. The second aim was 
to assess health care resources utilization after a first ICD implantation, highlight-
ing differences between implant indication (primary and secondary) or ICD type 
(single-chamber, dual-chamber and CRT-D). Methods: Data were extracted from: 
i) the data warehouse DENALI that organizes health care administrative databases 
concerning all subjects covered by Lombardy Health System; ii) ICD National registry 
data. Linking DENALI and registry data, we developed and validated (with Cohen’s 
kappa coefficient) an algorithm to distinguish hospitalizations for ICD in first implant 
and replacement in order to estimate the annual rates of first implant (per million 
person-years) and replacement (per hundred person-years). We selected a cohort 
of patients who underwent a first ICD implantation and we followed them until 
12/31/2010, recording vital status and health care resources consumed: hospitaliza-
tions, drugs and outpatient claims. Results: We identified 25,358 hospitalizations 
for ICD implantation: 17,864 for a first ICD and 8,034 for a replacement. 86% of hospi-
talizations found a match in the National registry and the Cohen’s kappa coefficient 
showed values over 0.8 from 2005. The annual rates were 232.5 (95%CI: 228.5-236.4) 
and 10.5 (95%CI: 10.3-10.7) for first ICD and replacement respectively. We selected a 
cohort of 12,525 patients who underwent a first ICD: 55% were implanted in primary 
prevention and the ICD types were: 35% single-chamber, 29% dual-chamber and 35% 
CRT-D. Among these groups, we detected differences in survival, ICD duration and 
health care resources utilization. ConClusions: The combined use of information 
from national ICD registry and health care administrative databases could overcome 
the limitation of both data sources and it could improve the monitoring of ICD therapy.
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objeCtives: The 12-lead electrocardiogram (ECG) is the current gold standard for 
the diagnosis of atrial fibrillation (AF). However, undertaking a 12-lead ECG is cum-
bersome, expensive and time consuming compared to a rhythm strip alone. The AF 
detection rate using a single lead ECG compared with a12-lead ECG amongst trainees 
of varying degrees of experience has not yet been reviewed in depth. Methods: 
Five doctors of different grades and specialties and one Cardiology Specialist Nurse 
sion models for costs and LOS used log transformation techniques. Results: A total 
of 62,527 patients (8,800 Bleeding; 53,727 Non-Bleeding) were included. Patients who 
received blood/blood products were significantly different in a number of baseline 
characteristics including Charlson Comorbidity Index. Unadjusted outcomes dem-
onstrated significant differences in mean total costs ($43,375 Bleeding; $18,411 Non-
Bleeding; p< 0.001) and LOS (13.62 Bleeding; 7.53 Non-Bleeding; p< 0.001) for patients 
who received blood products compared with those who did not. Multivariate models 
adjusting for patient characteristics demonstrated that patients who received blood/
blood products had 38.9% greater LOS and 34.3% greater ICU LOS. They also were 
3.53 times as likely to be admitted to the ICU, 3.75 times as likely to be readmitted 
for bleeding and 4.09 times as likely to die in hospital (all p< 0.001). Furthermore, 
they had 32.9% greater total cost of care including blood product cost and 31.8% 
greater total cost of care excluding blood product cost (both p< 0.001). ConClusions: 
Preventing or rapidly controlling emergent bleeding in trauma patients would likely 
reduce patient risk and avoid elevated costs of hospitalization.
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objeCtives: Hypertension (HTN) is a severe public health issue across the globe 
and a major risk factor for various cardiovascular diseases. This study was aimed 
to examine the potential costs of prognostic utilities and direct and indirect 
health care costs of the treatment of HTN in patients visiting public hospitals in 
Pakistan. Methods: A cross-sectional, convenient-sampling oriented study was 
conducted in patients attending public hospitals in Pakistan. The direct and indi-
rect health care costs were assessed by different variables i.e. consultation fees, 
cost of medicines, travelling costs, laboratory test expenses. All obtained data were 
analyzed using descriptive and inferential statistics. Results: The mean annual 
direct health care cost for a HTN patient was around PKRs. 19789.88 (US$ 201.21) 
and indirect health care cost was PKRs. 11990.90 (US$ 121.92). It was also observed 
that the mean indirect health care costs per patient were significantly varied 
(p < 0.001) among different public hospitals. ConClusions: Type of the HTN, dis-
tance to the hospital and length of stay in the hospital were proportional to the 
direct and indirect health care costs of the HTN patients. Better management of 
HTN can favorably impact the disease burden as untreated HTN or its comorbidi-
ties increase the overall treatment costs which affect affordability of the patient.
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objeCtives: Advances in the prevention and treatment of ischemic stroke and 
transient ischemic attack (TIA) during the past two decades have resulted in changes 
of medical practice. However, the existing cost estimates of ischemic stroke and 
TIA are based on resource use and cost data of approximately 20 years ago. We 
therefore determined hospital costs of ischemic stroke and TIA in the Netherlands 
for 2012. Methods: A retrospective cost analysis was conducted using patient 
and resource use data from the Diagnosis Treatment Combination (Diagnose 
Behandeling Combinatie) casemix system. Four subgroups were analysed: inpa-
tient ischemic stroke, inpatient TIA, outpatient ischemic stroke, and outpatient TIA. 
Additionally, we estimated the costs for carotid endarterectomy. Unit costs were 
based on 2012 reference prices of the Dutch Manual of Costing and tariffs provided 
by the Dutch Healthcare Authority. Ordinary least squares regression analysis was 
used to examine the association between hospital costs and various patient and 
hospital characteristics. Results: A total of 35,903 ischemic stroke and 21,653 TIA 
patients were included. Inpatient care costs for ischemic stroke were € 5,328 while 
the costs for TIA were € 2,470. Outpatient costs were estimated at € 495 for ischemic 
stroke and € 587 for TIA. Average hospital costs for carotid endarterectomy were 
estimated at € 6,836. The number of inpatient days was the greatest contributor 
to hospital costs for ischemic stroke and TIA patients. Age, type of hospital, and 
region were strong predictors of hospital costs. ConClusions: This study is the 
most recent and extensive cost analysis of inpatient and outpatient hospital costs 
of ischemic stroke and TIA patients. Our results may be used as input for economic 
evaluations and health economic models to support decision making about reim-
bursement, investment, and pricing of health care interventions.
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objeCtives: Cardiovascular events (CVE) are the number one cause of death (42%) 
in Germany. This study evaluates available literature regarding direct medical costs 
related to CVE in Germany. The CVE of interest were myocardial infarction (MI), unsta-
ble angina, heart failure (HF), stroke, and peripheral artery disease (PAD). Update of a 
review conducted in 2012. Methods: A systematic literature search was performed 
in the following databases- Medline, Embase, Centre for Reviews and Dissemination, 
TIBORDER, and German dissertation database from 01/2003 to 10/2013. Observational 
studies and randomized clinical trials were considered for the review. Results: The 
search identified 400 publications; 13 were included in this review. For MI, average hos-
pitalization costs during acute phase were between € 5,836 and € 7,522 per admission 
(PA). In the first year after a MI, direct medical costs were € 11,672 - 12,713 per patient. 
